Samar El Achy

Prof. Samar El Achy

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Indian Journal of Medical Microbiology
Verified
Journal Article
Closed access
MRMay Raouf
May Raouf
SESara Essa
Sara Essa
SASamar El Achy
Samar El Achy
MEMarwa Essawy
Marwa Essawy
SGsalma galal
salma galal
MBManal Baddour
Manal Baddour

29 May 2020 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
NANaglaa Agamia
Naglaa Agamia
ZAZoe Apalla
Zoe Apalla
SASamar El Achy
Samar El Achy
EAEman AbdelMaksoud
Eman AbdelMaksoud
NKNoha Kandil
Noha Kandil
SASami Abozeid
Sami Abozeid
Alopecia areata is an autoimmune form of non‐scarring hair loss Aim: to assess the serum concentration of IFN‐γ and CD8 cell expression in lesional skin biopsies in correlation with the disease severity, activity, duration and trichoscopic findings in patients with alopecia areata. Patients and methods: the study included 30 patients with AA and 15 age and sex matched healthy controls. Trichoscopy was performed and Photographs were captured for the alopecic areas, ELIZA technique was used for serum level of interferon‐gamma assessment and immunohistochemiistry for CD8 cells. Results: IFN‐γ serum level in patients was significantly higher compared to control subjects, and significantly correlated with the activity status and the duration of the disease. CD8+ T‐cells infiltrate intensity significantly correlated with sevrity. Yellow dots, vellus hair, black dot and exclamation marks were the most common trichoscopic findings. The presence of black dots significantly correlated to the disease activity, duration, serum IFN‐γ and CD8+ infiltrate intensity. The presence of yellow dots significantly correlated with the mean serum IFN‐γ level. Exclamation marks significantly correlated with the disease activity and the degree of CD8+ infiltrate. Conclusion: trichoscopy could be a reliable indicator of the IFN‐γ serum level and CD8 + T cell infiltrate intensity in AA patient.

5 August 2022 in Oral Diseases
Verified
Journal Article
Closed access
MEMarwa Essawy
Marwa Essawy
SRSalma T. Rafik
Salma T. Rafik
AAAshraf Awaad
Ashraf Awaad
GMGhada M. Mourad
Ghada M. Mourad
SASamar El Achy
Samar El Achy

5 March 2022 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
MEMohamed A. El-Emam
Mohamed A. El-Emam
SASamar El Achy
Samar El Achy
DADalaal M. Abdallah
Dalaal M. Abdallah
HEHanan S. Elabhar
Hanan S. Elabhar
MGMennatallah A. Gowayed
Mennatallah A. Gowayed
Background: Mitoxantrone has proved efficacy in treatment of multiple sclerosis (MS). The fact that physical exercise could slow down the progression of disease and improve performance is still a debatable issue, hence; we aimed at studying whether combining mitoxantrone with exercise is of value in the management of MS. Methods: Thirty-six male rats were divided into sedentary and exercised groups. During a 14-day habituation period rats were subjected to exercise training on a rotarod (30 min/day) before Experimental Autoimmune Encephalomyelitis (EAE) induction and thereafter for 17 consecutive days. On day 13 after induction, EAE groups (exercised &sedentary) were divided into untreated and mitoxantrone treated ones. Disease development was evaluated by motor performance and EAE score. Cerebrospinal fluid (CSF) was used for biochemical analysis. Brain stem and cerebellum were examined histopathological and immunohistochemically. Results: Exercise training alone did not add a significant value to the studied parameters, except for reducing Foxp3 immunoreactivity in EAE group and caspase-3 in the mitoxantrone treated group. Unexpectedly, exercise worsened the mitoxantrone effect on EAE score, Bcl2 and Bax. Mitoxantrone alone decreased EAE/demyelination/inflammation scores, Foxp3 immunoreactivity, and interleukin-6, while increased the re-myelination marker BDNF without any change in tumor necrosis factor-α. It clearly interrupted the apoptotic pathway in brain stem, but worsened EAE mediated changes of the anti-apoptotic Bcl2 and pro-apoptotic marker Bax in the CSF. Conclusions: The neuroprotective effect of mitoxantrone was related with remyelination, immunosuppressive and anti-inflammatory potentials. Exercise training did not show added value to mitoxantrone, in contrast, it disrupts the apoptotic pathway.

1 November 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
HAHany S M Ali
Hany S M Ali
AHAhmed F Hanafy
Ahmed F Hanafy
RBRawan Bafail
Rawan Bafail
HAHamad Alrbyawi
Hamad Alrbyawi
MAMarey Almaghrabi
Marey Almaghrabi
SASamar El Achy
Samar El Achy
Background: Budesonide (BUD) is a BCS class II medication with poor water solubility and limited oral bioavailability. In this study, innovative solid self-microemulsifying drug delivery systems (BUD-SMEDDS) were developed for effective local management of distal ulcerative colitis (UC). Methods: Based on solubility and emulsification tests, the components of the self-microemulsifying drug delivery system (SMEDDS) were Capryol™ 90, Tween 80, and Transcutol HP. The impacts of BUD-SMEDDS ingredients (as inputs) on the average globule size (AGS), polydispersity index (PDI), and self-emulsification time (SET) as responses were investigated using the Box–Behnken design methodology. Solid rectal systems were then fabricated using the optimized values of SMEDDS components in Lutrol® bases. The developed systems were evaluated for in vitro characteristics and in vivo efficacy using a rat colitis model. Results: For all responses, the greatest impact was attributed to the oil content of SMEDDS. An optimized BUD-SMEDDS with AGS of 33 ± 2.9 nm, PDI of 0.29 ± 0.03 and SET of 25 ± 2.5 s) was selected for rectal formulations. The developed formulations demonstrated acceptable physical characteristics and mucoadhesive abilities. Differential scanning calorimetric (DSC) analysis revealed the absence of BUD crystallinity in the SMEDDS formulations. The drug release patterns could be regulated by selecting the grade and composition of the incorporated Lutrols. Clinical and histopathological assessments revealed considerable improvements in animals treated with BUD-SMEDDS formulations. Conclusion: Overall findings confirmed the superior capability of solid SMEDDS as BUD carriers to manage distal colitis in tested animals.

21 November 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
NENoha S. El-Salamouni
Noha S. El-Salamouni
MGMennatallah A. Gowayed
Mennatallah A. Gowayed
SASamar El Achy
Samar El Achy
MSMaha El Shahawy
Maha El Shahawy
Doaa A GhareebDoaa A Ghareeb
Doaa A Ghareeb
GLGihan Salah Labib
Gihan Salah Labib